Biological & Psychological Factors as Predictors & Indicators of MBSR Response

生物

基本信息

  • 批准号:
    8848039
  • 负责人:
  • 金额:
    $ 43.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-01 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this RO1 project is to develop and validate a set "platform" of biological and psychological characteristics (i.e., biopsychomarkers) that predict and indicate patient (Pt) response to mindfulness-based stress reduction (MBSR) and verify that a tailored MBSR approach improves the quality and consistency of MBSR on disease outcomes. Our preliminary data demonstrate that only a subset of ulcerative colitis (UC) Pts respond to MBSR with improved disease outcomes which is in agreement with the literature which reports similar mixed outcomes with mindfulness therapy when it has been applied to other diseases, suggesting that certain biopsychomarkers may impact success. Thus, we hypothesize that the differential responses to MBSR are a consequence of individual variance in biopsychomarkers at the onset of MBSR therapy. The objective of the current proposal is then to identify and verify predictive biopsychomarkers and reliable measurable outcomes as determinants of MBSR success. To achieve this objective we propose two Specific Aims. Aim1: Develop a set of biopsychomarkers, comprised of key psychological and biological characteristics that (a) predict UC Pt response to MBSR and (b) establish an objective set of markers that demonstrate the impact of MBSR on well-being and UC disease state. Aim 2: Verify the impact of Pt and intervention tailoring in order to determine whether (a) tailoring Pt selection based on biopsychomarkers, and whether (b) tailoring of MBSR treatment protocol will impact MBSR's effects on inflammatory pathways and markers of disease and psychological well-being in UC Pts. Accomplishing these Aims will establish an objective set of Pt characteristics that predict effectiveness of MBSR resulting in increased quality and consistency of MBSR as a therapeutic approach. This should open new innovative therapeutic applications for MBSR for the treatment of chronic inflammatory diseases.
描述(由申请人提供):本RO1项目的总体目标是开发和验证一套生物和心理特征的“平台”(即,生物心理标志物),其预测和指示患者(Pt)对基于正念的减压(MBSR)的反应,并验证定制的MBSR方法改善了MBSR对疾病结果的质量和一致性。我们的初步数据表明,只有一部分溃疡性结肠炎(UC)患者对正念减压疗法有反应,疾病结局得到改善,这与文献报道的正念疗法应用于其他疾病时的类似混合结局一致,表明某些生物心理标志物可能会影响成功。因此,我们假设对正念减压疗法的不同反应是正念减压疗法开始时生物心理标志物个体差异的结果。目前的建议的目的是识别和验证预测生物心理标志物和可靠的可测量的结果作为正念减压疗法成功的决定因素。为了实现这一目标,我们提出了两个具体目标。目标1:开发一组生物心理标志物,包括关键的心理和生物学特征,(a)预测UC Pt对MBSR的反应,(B)建立一组客观的标志物,证明MBSR对健康和UC疾病状态的影响。目标二:验证患者和干预措施定制的影响,以确定(a)是否基于生物心理标志物定制患者选择,以及(B)是否定制MBSR治疗方案将影响MBSR对UC患者的炎症通路和疾病标志物以及心理健康的影响。实现这些目标将建立一组客观的Pt特征,预测MBSR的有效性,从而提高MBSR作为治疗方法的质量和一致性。这将为正念减压治疗慢性炎症性疾病开辟新的创新治疗应用。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial.
正念干预可降低非活动性溃疡性结肠炎患者发作的频率和严重程度:II 期随机安慰剂对照试验的结果。
  • DOI:
    10.1093/ibd/izac036
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    4.9
  • 作者:
    Jedel,Sharon;Beck,Todd;Swanson,Garth;Hood,MeganM;Voigt,RobinM;Gorenz,Annika;Jakate,Shriram;Raeisi,Shohreh;Hobfoll,Stevan;Keshavarzian,Ali
  • 通讯作者:
    Keshavarzian,Ali
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVAN HOBFOLL其他文献

STEVAN HOBFOLL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVAN HOBFOLL', 18)}}的其他基金

Research Training/Educaiton Core
研究培训/教育核心
  • 批准号:
    8356077
  • 财政年份:
    2012
  • 资助金额:
    $ 43.93万
  • 项目类别:
Biological & Psychological Factors as Predictors & Indicators of MBSR Response
生物
  • 批准号:
    8672599
  • 财政年份:
    2011
  • 资助金额:
    $ 43.93万
  • 项目类别:
Biological & Psychological Factors as Predictors & Indicators of MBSR Response
生物
  • 批准号:
    8321478
  • 财政年份:
    2011
  • 资助金额:
    $ 43.93万
  • 项目类别:
Biological & Psychological Factors as Predictors & Indicators of MBSR Response
生物
  • 批准号:
    8496498
  • 财政年份:
    2011
  • 资助金额:
    $ 43.93万
  • 项目类别:
Biological & Psychological Factors as Predictors & Indicators of MBSR Response
生物
  • 批准号:
    8261561
  • 财政年份:
    2011
  • 资助金额:
    $ 43.93万
  • 项目类别:
STRESS MEASURES/PSYCHOMETRICS
压力测量/心理测量
  • 批准号:
    7881326
  • 财政年份:
    2010
  • 资助金额:
    $ 43.93万
  • 项目类别:
Terrorism and Traumatic Responding: Exposure and Resiliency Factors
恐怖主义和创伤反应:暴露和复原力因素
  • 批准号:
    7689862
  • 财政年份:
    2006
  • 资助金额:
    $ 43.93万
  • 项目类别:
Terrorism and Traumatic Responding: Exposure and Resiliency Factors
恐怖主义和创伤反应:暴露和复原力因素
  • 批准号:
    7263144
  • 财政年份:
    2006
  • 资助金额:
    $ 43.93万
  • 项目类别:
Terrorism and Traumatic Responding: Exposure and Resiliency Factors
恐怖主义和创伤反应:暴露和复原力因素
  • 批准号:
    7497127
  • 财政年份:
    2006
  • 资助金额:
    $ 43.93万
  • 项目类别:
Terrorism and Traumatic Responding: Exposure and Resiliency Factors
恐怖主义和创伤反应:暴露和复原力因素
  • 批准号:
    7139454
  • 财政年份:
    2006
  • 资助金额:
    $ 43.93万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 43.93万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 43.93万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 43.93万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 43.93万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 43.93万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 43.93万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 43.93万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 43.93万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 43.93万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 43.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了